Dynavax Universal Flu Vaccine

Dynavax Universal Flu Vaccine refers to a development program by Dynavax Technologies focused on creating a broadly protective influenza vaccine. The lead candidate is a universal vaccine that combines Dynavax's proprietary Toll-like receptor 9 (TLR9) agonist (a second-generation immunostimulatory sequence, such as CpG 1018) with two highly conserved influenza antigens: nucleoprotein (NP) and the extracellular domain of matrix protein 2 (M2e). This formulation is designed to be used in conjunction with standard trivalent influenza vaccines to enhance immune responses. The mechanism of action involves stimulating cytotoxic T-cell responses via the NP antigen and cytotoxic antibody responses via the M2e antigen, while the TLR9 agonist acts as an adjuvant to boost the production of neutralizing antibodies against seasonal hemagglutinin components. The program also includes a pandemic H5N1 vaccine candidate and a collaboration with Mount Sinai utilizing chimeric hemagglutinin (cHA) technology.

Other names

Universal Influenza VaccineNP-M2e-ISS vaccineNP-M-2e-ISS vaccineNP-M 2e-ISS vaccine